|
|
Article: MethylGene Reports Third Quarter 2009 Financial Results.(Financial report)
- Article from:
- Marketwire Canada
- Article date:
- November 5, 2009
CopyrightCOPYRIGHT 2009 Canadian Corporate News. News Provided by Comtex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MONTREAL, QUEBEC, Nov 5, 2009 (Marketwire via COMTEX) -- MethylGene Inc. (TSX:MYG) today announced financial results for the third quarter ended September 30, 2009.
Operational highlights of the quarter include:
- The U.S. Food and Drug Administration lifted the partial clinical hold for new patient enrollment previously placed on mocetinostat (MGCD0103), a histone deacetylase inhibitor for cancer. With the partial hold lifted, the Company expects to enroll new patients as soon as possible in its Phase II clinical trial in patients with relapsed or refractory follicular lymphoma (Trial 008).
- The Company initiated its Phase II program for ...